1
|
Maza PAMA, Lee JH, Kim YS, Sun GM, Sung YJ, Ponomarenko LP, Stonik VA, Ryu M, Kwak JY. Inotodiol From Inonotus obliquus Chaga Mushroom Induces Atypical Maturation in Dendritic Cells. Front Immunol 2021; 12:650841. [PMID: 33777049 PMCID: PMC7994266 DOI: 10.3389/fimmu.2021.650841] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 02/25/2021] [Indexed: 12/29/2022] Open
Abstract
Dendritic cells (DCs) have the ability to stimulate naïve T cells that coordinate subsequent adaptive response toward an inflammatory response or tolerance depending on the DC differentiation level. Inotodiol, a lanostane triterpenoid found in Inonotus obliquus (wild Chaga mushroom), is a natural compound with a wide range of biological activities. In this study, we investigated whether inotodiol promotes the maturation of bone marrow-derived DCs (BMDCs) and inotodiol-treated BMDCs induce T cell activation. Inotodiol increased the expression of surface maturation markers, including MHC-I, MHC-II, CD86, and CD40, on BMDCs without affecting the production of various cytokines, including TNF-α and IL-12p40 in these cells. T cells primed with inotodiol-treated BMDCs proliferated and produced IL-2, without producing other cytokines, including IL-12p40 and IFN-γ. Injection of inotodiol into mice induced maturation of splenic DCs and IL-2 production, and the administration of inotodiol and inotodiol-treated BMDCs induced the proliferation of adoptively transferred CD8+ T cells in vivo. The phosphatidylinositol-3-kinase inhibitor wortmannin abrogated the upregulation of Akt phosphorylation and CD86 and MHC-II expression induced by inotodiol. However, inotodiol failed to induce phosphorylation of the IκB kinase and degradation of IκB-α, and increased expression of CD86 induced by inotodiol was not blocked by an IκB kinase inhibitor. These results suggest that inotodiol induces a characteristic type of maturation in DCs through phosphatidylinositol-3-kinase activation independent of NF-κB, and inotodiol-treated DCs enhance T cell proliferation and IL-2 secretion.
Collapse
Affiliation(s)
- Perry Ayn Mayson A Maza
- Department of Pharmacology, School of Medicine, Ajou University, Suwon, South Korea.,Department of Biomedical Sciences, The Graduate School, Ajou University, Suwon, South Korea
| | - Ji-Hyun Lee
- Department of Pharmacology, School of Medicine, Ajou University, Suwon, South Korea.,Department of Biomedical Sciences, The Graduate School, Ajou University, Suwon, South Korea
| | - Yong-Su Kim
- Department of Pharmacology, School of Medicine, Ajou University, Suwon, South Korea.,Department of Biomedical Sciences, The Graduate School, Ajou University, Suwon, South Korea
| | - Gyu-Min Sun
- Department of Pharmacology, School of Medicine, Ajou University, Suwon, South Korea.,Department of Biomedical Sciences, The Graduate School, Ajou University, Suwon, South Korea
| | - Youn-Joo Sung
- Department of Pharmacology, School of Medicine, Ajou University, Suwon, South Korea.,Department of Biomedical Sciences, The Graduate School, Ajou University, Suwon, South Korea
| | - Ludmila P Ponomarenko
- G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of the Russian Academy of Sciences, Vladivostok, Russia
| | - Valentine A Stonik
- G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of the Russian Academy of Sciences, Vladivostok, Russia
| | - Minsook Ryu
- Department of Allergy, School of Medicine, Ajou University, Suwon, South Korea
| | - Jong-Young Kwak
- Department of Pharmacology, School of Medicine, Ajou University, Suwon, South Korea.,Immune Network Pioneer Research Center, Ajou University, Suwon, South Korea.,3D Immune System Imaging Core Center, Ajou University, Suwon, South Korea
| |
Collapse
|
2
|
Yoon H, Fuchs C, Özgüroğlu M, Bang Y, Bartolomeo MD, Mandala M, Ryu M, Fornaro L, Olesinski T, Caglevic C, Chung H, Muro K, Cutsem EV, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Wang A, Bhagia P, Lin J, Shih C, Shitara K. O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.065] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Zasso F, You-Ten K, Ryu M, Losyeva K, Tanwani J, Siddiqui N. Complications of cricothyrotomy and tracheostomy in emergency surgical airway management: a systematic review. Br J Anaesth 2020. [DOI: 10.1016/j.bja.2020.04.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Vasiliev A, Canepa S, Ferroukhi H, Boyarinov V, Fomichenko P, Joo H, Ryu M. Cross-verification of SUHAM-TD and nTracer reactivity insertion transient solutions without materials homogenization approximation using OECD/NEA C5G7-TD benchmark. ANN NUCL ENERGY 2019. [DOI: 10.1016/j.anucene.2019.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Zakhari A, Edwards DL, Ryu M, Bougie O, Murji A. Post-Operative Dienogest Following Conservative Endometriosis Surgery: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol 2019. [DOI: 10.1016/j.jmig.2019.09.049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Kang Y, Chin K, Chung H, Kadowaki S, Oh S, Nakayama N, Lee K, Hara H, Chung I, Tsuda M, Park S, Hosaka H, Hironaka S, Miyata Y, Ryu M, Takeuchi M, Baba H, Hyodo I, Bang Y, Boku N. A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz183.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
An E, Ryu M, Yan D, Park Y, Na H, Ma J, Tian Y, Cecchi F, Hembrough T, Kang Y. Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Ryu M, Li W. 2106 Non-surgical HIPEC in the treatment of late stage cancer with malignant ascites. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31028-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Kanlaya R, Sintiprungrat K, Thongboonkerd V, Torremade N, Bindels R, Hoenderop J, Fernandez E, Dusso A, Valdivielso JM, Krueger T, Boor P, Schafer C, Westenfeld R, Brandenburg V, Schlieper G, Jahnen-Dechent W, Ketteler M, Jee W, Li X, Richards B, Floege J, Goncalves JG, Canale D, de Braganca AC, Shimizu MHM, Moyses RMA, Andrade L, Seguro AC, Volpini RA, Romoli S, Migliorini A, Anders HJ, Eskova O, Neprintseva N, Tchebotareva N, Bobkova I, Kozlovskaya L, Simic I, Tabatabaeifar M, Wlodkowski T, Denc H, Mollet G, Antignac C, Schaefer F, Ekaterina IA, Giardino L, Rastaldi MP, Van den Heuvel L, Levtchenko E, Okina C, Okamoto T, Kamata M, Murano J, Kobayashi K, Takeuchi K, Kamata F, Sakai T, Naito S, Aoyama T, Sano T, Takeuchi Y, Kamata K, Thomasova D, Bruns HA, Liapis H, Anders HJ, Iwashita T, Hasegawa H, Takayanagi K, Shimizu T, Asakura J, Okazaki S, Kogure Y, Hatano M, Hara H, Inamura M, Iwanaga M, Mitani T, Mitarai T, Savin VJ, Sharma M, Wei C, Reiser J, McCarthy ET, Sharma R, Gauchat JF, Eneman B, Freson K, Van den Heuvel L, Van Geet C, Levtchenko E, Choi DE, Jeong JY, Chang YK, Na KR, Lee KW, Shin YT, Ni HF, Chen JF, Zhang MH, Pan MM, Liu BC, Lee KW, Jeong JY, Choi DE, Chang YK, Kim SS, Na KR, Shin YT, Suzuki T, Iyoda M, Matsumoto K, Shindo-Hirai Y, Kuno Y, Wada Y, Yamamoto Y, Shibata T, Akizawa T, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Ehling J, Babickova J, Gremse F, Kiessling F, Floege J, Lammers T, Boor P, Lech M, Gunthner R, Lorenz G, Ryu M, Grobmayr R, Susanti H, Kobayashi KS, Flavell RA, Anders HJ, Rayego-Mateos S, Morgado J, Sanz AB, Eguchi S, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M, Leduc M, Geerts L, Grouix B, Sarra-Bournet F, Felton A, Gervais L, Abbott S, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Detsika MG, Duann P, Lianos EA, Leong KI, Chiang CK, Yang CC, Wu CT, Chen LP, Hung KY, Liu SH, Carvalho FF, Teixeira VP, Almeida WS, Schor N, Small DM, Bennett NC, Coombes J, Johnson DW, Gobe GC, Montero N, Prada A, Riera M, Orfila M, Pascual J, Rodriguez E, Barrios C, Kokeny G, Fazekas K, Rosivall L, Mozes MM, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Hornigold N, Hughes J, Mooney A, Benardeau A, Riboulet W, Vandjour A, Jacobsen B, Apfel C, Conde-Knape K, Grouix B, Felton A, Sarra-Bournet F, Leduc M, Geerts L, Gervais L, Abbott S, Bienvenu JF, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Tanaka T, Yamaguchi J, Nangaku M, Niwa T, Bolati D, Shimizu H, Yisireyili M, Nishijima F, Brocca A, Virzi G, de Cal M, Ronco C, Priante G, Musacchio E, Valvason C, Sartori L, Piccoli A, Baggio B, Boor P, Perkuhn M, Weibrecht M, Zok S, Martin IV, Schoth F, Ostendorf T, Kuhl C, Floege J, Karabaeva A, Essaian A, Beresneva O, Parastaeva M, Kayukov I, Smirnov A, Audzeyenka I, Kasztan M, Piwkowska A, Rogacka D, Angielski S, Jankowski M, Bockmeyer CL, Kokowicz K, Agustian PA, Zell S, Wittig J, Becker JU, Nishizono R, Venkatareddy MP, Chowdhury MA, Wang SQ, Fukuda A, Wickman LT, Yang Y, Wiggins RC, Fazio MR, Donato V, Lucisano S, Cernaro V, Lupica R, Trimboli D, Montalto G, Aloisi C, Mazzeo AT, Buemi M, Gawrys O, Olszynski KH, Kuczeriszka M, Gawarecka K, Swiezewska E, Chmielewski M, Masnyk M, Rafalowska J, Kompanowska-Jezierska E, Lee WC, Chau YY, Lee LC, Chiu CH, Lee CT, Chen JB, Kim WK, Shin SJ. Experimental models of CKD. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Choi JD, Ryu M, Ae Park M, Jeong G, Lee JS. FIP200 inhibits β-catenin-mediated transcription by promoting APC-independent β-catenin ubiquitination. Oncogene 2012; 32:2421-32. [PMID: 22751121 DOI: 10.1038/onc.2012.262] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Focal adhesion kinase-family-interacting protein of 200 kDa (FIP200) has been shown to regulate multiple cellular functions, including cell adhesion, autophagy, development and proliferation. Furthermore, FIP200 is considered to have tumor-suppressive activity, which may be correlated with its inactivation in human breast cancers, in addition to its role as an important signal transduction node. Herein, we report that FIP200 interacts with the oncoprotein β-catenin. Moreover, FIP200 promotes destabilization of wild-type β-catenin, but not a cancer-causing form of β-catenin, and as a result represses the β-catenin-mediated transcription. FIP200-induced degradation of β-catenin is independent of adenomatous polyposis coli (APC) of the well-established β-catenin destruction complex (glycogen synthase kinase-3β/axin/APC), in a component of β-catenin E3 ubiquitin ligase, β-TrCP-dependent manner. Thus, the APC-independent β-catenin degradation by FIP200 suggests a role for FIP200 in tumor suppression in the presence of APC dysfunction. These findings reveal a new and important function of FIP200 in regulation of the Wnt/β-catenin pathway.
Collapse
Affiliation(s)
- J D Choi
- Department of Molecular Science and Technology, College of Natural Sciences, Ajou University, Suwon, Korea
| | | | | | | | | |
Collapse
|
11
|
Cruz D, De Geus HR, Ronco C, Groeneveld ABJ, Kulkarni OP, Hagemann JH, Mulay SR, Thomasova D, Ryu M, Anders HJ. New advances in the pathophysology of AKI. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs190] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Yi Chun DX, Alexandre H, Edith B, Nacera O, Julie P, Chantal J, Eric R, Zhang X, Jin Y, Miravete M, Dissard R, Klein J, Gonzalez J, Caubet C, Pecher C, Pipy B, Bascands JL, Mercier-Bonin M, Schanstra J, Buffin-Meyer B, Claire R, Rigothier C, Richard D, Sebastien L, Moin S, Chantal B, Christian C, Jean R, Migliori M, Migliori M, Cantaluppi V, Mannari C, Medica D, Giovannini L, Panichi V, Goldwich A, Alexander S, Andre G, Amann K, Migliorini A, Sagrinati C, Angelotti ML, Mulay SR, Ronconi E, Peired A, Romagnani P, Anders HJ, Chiang WC, Lai CF, Peng WH, Wu CF, Chang FC, Chen YT, Lin SL, Chen YM, Wu KD, Lu KS, Tsai TJ, Virgine O, Qing Feng F, Zhang SY, Dominique D, Vincent A, Marina C, Philippe L, Georges G, Pawlak A, Sahali D, Matsumoto S, Kiyomoto H, Ichimura A, Dan T, Nakamichi T, Tsujita T, Akahori K, Ito S, Miyata T, Xie S, Zhang B, Shi W, Yang Y, Nagasu H, Satoh M, Kidokoro K, Nishi Y, Ihoriya C, Kadoya H, Sasaki T, Kashihara N, Wu CF, Chang FC, Chen YT, Chou YH, Duffield J, Lin SL, Rocca C, Rocca C, Gregorini M, Corradetti V, Valsania T, Bedino G, Bosio F, Pattonieri EF, Esposito P, Sepe V, Libetta C, Rampino T, Dal Canton A, Bedino G, Gregorini M, Corradetti V, Rocca C, Pattonieri EF, Valsania T, Bosio F, Esposito P, Sepe V, Libetta C, Rampino T, Dal Canton A, Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y, Rakugi H, Wasilewska A, Taranta-Janusz K, Deebek W, Kuroczycka-Saniutycz E, Lee AS, Lee AS, Lee JE, Jung YJ, Kang KP, Lee S, Kim W, Arfian N, Emoto N, Yagi K, Nakayama K, Hartopo AB, Nugrahaningsih DA, Yanagisawa M, Hirata KI, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Oujo B, Munoz-Felix JM, Arevalo M, Bernabeu C, Perez-Barriocanal F, Lopez-Novoa JM, Jesper K, Nathalie V, Pierre G, Yi Chun DX, Alexandre H, Eric R, Iyoda M, Shibata T, Matsumoto K, Shindo-Hirai Y, Kuno Y, Wada Y, Akizawa T, Schwartz I, Schwartz D, Prot Bertoye C, Prot Bertoye C, Terryn S, Claver J, Beghdadi WB, Monteiro R, Blank U, Devuyst O, Daugas E, Van Beneden K, Geers C, Pauwels M, Mannaerts I, Van den Branden C, Van Grunsven LA, Seckin I, Pekpak M, Uzunalan M, Uruluer B, Kokturk S, Ozturk Z, Sonmez H, Yaprak E, Furuno Y, Tsutsui M, Morishita T, Shimokawa H, Otsuji Y, Yanagihara N, Kabashima N, Ryota S, Kanegae K, Miyamoto T, Nakamata J, Ishimatsu N, Tamura M, Nakagawa T, Nakagawa T, Ichikawa K, Miyamoto M, Takabayashi D, Yamazaki H, Kakeshita K, Koike T, Kagitani S, Tomoda F, Hamashima T, Ishii Y, Inoue H, Sasahara M, El Machhour F, Kerroch M, Mesnard L, Chatziantoniou C, Dussaule JC, Inui K, Sasai F, Maruta Y, Nishiwaki H, Kawashima E, Inoue Y, Yoshimura A, Matsumoto K, Matsumoto K, Iyoda M, Shibata T, Wada Y, Shindo-Hirai Y, Kuno Y, Akizawa T, Musacchio E, Priante G, Valvason C, Sartori L, Baggio B, Kim JH, Gross O, Diana R, Gry DH, Asimal B, Johanna T, Imke SE, Lydia W, Gerhard-Anton M, Hassan D, Cano JL, Griera M, Olmos G, Martin P, Cortes MA, Lopez-Ongil S, Rodriguez-Puyol D, DE Frutos S, Gonzalez M, DE Frutos S, Cano JL, Luengo A, Martin P, Rodriguez-Puyol M, Calleros L, Lupica R, Lacquaniti A, Donato V, Maggio R, Mastroeni C, Lucisano S, Cernaro V, Fazio MR, Quartarone A, Buemi M, Kacik M, Goedicke S, Eggert H, Hoyer JD, Wurm S, Wurm S, Steege A, Banas M, Kurtz A, Banas B, Lasagni L, Lazzeri E, Peired A, Angelotti ML, Ronconi E, Romoli S, Romagnani P, Schaefer I, Teng B, Worthmann K, Haller H, Schiffer M, Prattichizzo C, Netti GS, Rocchetti MT, Cormio L, Carrieri G, Stallone G, Grandaliano G, Ranieri E, Gesualdo L, Kucher A, Smirnov A, Parastayeva M, Beresneva O, Kayukov I, Zubina I, Ivanova G, Abed A, Schlekenbach L, Foglia B, Chatziantoniou C, Kwak B, Chadjichristos C, Queisser N, Schupp N, Brand S, Himer L, Himer L, Szebeni B, Sziksz E, Saijo S, Kis E, Prokai A, Banki NF, Fekete A, Tulassay T, Vannay A, Hegner B, Schaub T, Lange C, Dragun D, Klinkhammer BM, Rafael K, Monika M, Anna M, Van Roeyen C, Boor P, Eva Bettina B, Simon O, Esther S, Floege J, Kunter U, Hegner B, Janke D, Schaub T, Lange C, Jankowski J, Dragun D, Hayashi M, Takamatsu I, Horimai C, Yoshida T, Seno DI Marco G, Koenig M, Stock C, Reiermann S, Amler S, Koehler G, Fobker M, Buck F, Pavenstaedt H, Lang D, Brand M, Plotnikov E, Morosanova M, Pevzner I, Zorova L, Pulkova N, Zorov D, Wornle M, Ribeiro A, Belling F, Merkle M, Nakazawa D, Nishio S, Shibasaki S, Tomaru U, Akihiro I, Kobayashi I, Imanishi Y, Kurajoh M, Nagata Y, Yamagata M, Emoto M, Michigami T, Ishimura E, Inaba M, Nishi Y, Satoh M, Sasaki T, Kashihara N, Wu CC, Lu KC, Chen JS, Chu P, Lin YF, Eller K, Schroll A, Banas M, Kirsch A, Huber J, Weiss G, Theurl I, Rosenkranz AR, Zawada A, Rogacev K, Achenbach M, Fliser D, Held G, Heine GH, Miyamoto Y, Iwao Y, Watanabe H, Kadowaki D, Ishima Y, Chuang VTG, Sato K, Otagiri M, Maruyama T, Ueda Y, Iwatani H, Isaka Y, Watanabe H, Honda D, Miyamoto Y, Noguchi T, Kadowaki D, Ishima Y, Tanaka M, Tanaka H, Fukagawa M, Otagiri M, Maruyama T, Wornle M, Ribeiro A, Pircher J, Koppel S, Mannell H, Krotz F, Merkle M, Virzi GM, Bolin C, Cruz D, Scalzotto E, De Cal M, Vescovo G, Ronco C, Virzi GM, Bolin C, Cruz D, Scalzotto E, De Cal M, Vescovo G, Ronco C, Grobmayr R, Lech M, Ryu M, Anders HJ, Aoshima Y, Mizobuchi M, Ogata H, Kumata C, Nakazawa A, Kondo F, Ono N, Koiwa F, Kinugasa E, Akizawa T, Freisinger W, Lale N, Lampert A, Ditting T, Heinlein S, Schmieder RE, Veelken R, Nave H, Perthel R, Suntharalingam M, Bode-Boger S, Beutel G, Kielstein J, Rodrigues-Diez R, Rodrigues-Diez R, Rayego-Mateos S, Lavoz C, Stark Aroeira LG, Orejudo M, Alique M, Ortiz A, Egido J, Ruiz-Ortega M, Oskar W, Rusan C, Schaub T, Hegner B, Dragun D, Padberg JS, Wiesinger A, Brand M, Seno DI Marco G, Reuter S, Grabner A, Kentrup D, Lukasz A, Oberleithner H, Pavenstadt H, Kumpers P, Eberhardt HU, Skerka C, Chen Q, Hallstroem T, Hartmann A, Kemper MJ, Zipfel PF, N'gome-Sendeyo K, Fan QF, Zhang SY, Pawlak A, Sahali D, Wornle M, Ribeiro A, Merkle M, Toblli J, Toblli J, Cao G, Giani JF, Dominici FP, Kim JS, Yang JW, Kim MK, Han BG, Choi SO. Experimental pathology. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Noguchi E, Koval N, Andoh T, Ryu M, Yamamoto M. Investigative study on the antimicrobial activity and effects of virucidal hand antiseptic on skin. BMC Proc 2011. [PMCID: PMC3239697 DOI: 10.1186/1753-6561-5-s6-p268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
14
|
Lech M, Kantner C, Kulkarni OP, Ryu M, Vlasova E, Heesemann J, Anz D, Endres S, Kobayashi KS, Flavell RA, Martin J, Anders HJ. Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus. Ann Rheum Dis 2011; 70:2207-17. [DOI: 10.1136/ard.2011.155515] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
15
|
Nagasaki Y, Yoshitomi T, Hirayama A, Schock-Kusch D, Xie Q, Shulhevich Y, Hesser J, Stsepankou S, Koenig S, Heinrich R, Pill J, Gretz N, Efrati S, Berman S, Abu-Hamad R, Siman-Tov Y, Weissgarten J, Kimura T, Takabatake Y, Takahashi A, Kaimori JY, Matsui I, Namba T, Kitamura H, Niimura F, Matsusaka T, Rakugi H, Isaka Y, Ito K, Watanabe M, Nakashima H, Abe Y, Ifuku M, Nishimura S, Saito T, Mulay SR, Thomasova D, Ryu M, Anders HJ, Nakayama Y, Ueda S, Yamagishi SI, Ando R, Kaida Y, Iwatani R, Fujimi A, Fukami K, Okuda S, Shin YT, Jeong JY, Jang WI, Chung S, Choi DE, Na KR, Lee KW, Mugitani N, Shimizu Y, Satake K, Suzuki Y, Horikoshi S, Tomino Y, Schneider R, Meusel M, Betz B, Wanner C, Koepsell H, Sauvant C, Dursun B, Abban G, Kucukatay V, Tufan L, Dodurga Y, Guclu A, Gok D, Vicente-Vicente L, Sanchez-Gonzalez PD, Prieto M, Lopez-Novoa JM, Lopez-Hernandez FJ, Morales AI, Torres A, Dnyanmote A, Wu W, Nigam S, Wystrychowski A, Wystrychowski W, Kolodziejczyk A, Obuchowicz E, Wiecek A, Sanchez-Gonzalez PD, Vicente-Vicente L, Prieto M, Lopez-Hernandez FJ, Lopez-Novoa JM, Morales AI, Reis LA, Borges FT, Simoes MDJ, Schor N, Mesnard L, Rafat C, Vandermeersch S, Nochy D, Garcon L, Callard P, Jouanneau C, Verpont MC, Hertig A, Rondeau E, Grosjean F, Torreggiani M, Esposito V, Mangione F, Serpieri N, Villa L, Sileno G, Marchi G, Fasoli G, Esposito C, Dal Canton A, Sancho-Martinez S, Lopez-Novoa JM, Lopez-Hernandez FJ, Esposito V, Grosjean F, Striker G, Vlassara H, Zheng F, Park DJ, Kim JH, Jung MH, Seo JW, Kim HJ, Chang SH, Han BG, Yang JW, Yu JM, Choi SO, Efrati S, Berman S, Abu-Hamad R, Siman-Tov Y, Weissgarten J, Reis LA, Christo JS, Simoes MDJ, Schor N, Rusai K, Prokai A, Szebeni B, Meszaros K, Fekete A, Treszl A, Vannay A, Muller V, Reusz G, Heemann U, Tulassay T, Lutz J, Szabo AJ, Ranghino A, Bruno S, Grange C, Dolla C, Cantaluppi V, Biancone L, Tetta C, Segoloni GP, Camussi G, Pinto V, Teixeira V, Almeida W, Schor N, Reis LA, Borges FT, Simoes MDJ, Schor N, Fujikura T, Sun Y, Iwakura T, Yasuda H, Fujigaki Y, Simone S, Rascio F, Loverre A, Cosola C, Cariello M, Castellano G, Ditonno P, Schena FP, Gesualdo L, Grandaliano G, Pertosa G, Choi JY, Kim J, Jin DC, Cha JH, Vicente-Vicente L, Prieto M, Sanchez-Gonzalez PD, Lopez-Novoa JM, Lopez-Hernandez FJ, Morales AI, Kaynar K, Aliyazicioglu R, Ersoz S, Ulusoy S, Al S, Ozkan G, Cansiz M, Fuchs TC, Emde B, Czasch S, von Landenberg F, Hewitt P, Abu-Salah N, Bishara B, Awad H, Ghrayeb N, Assady S, Armaly Z, Better O, Abassi Z. Acute kidney injury - Experimental models. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Noh H, Kim HJ, Yu MR, Ryu JH, Kim JH, Kim E, Han DC, Bedino G, Rampino T, Gregorini M, Valsania T, Rocca C, Corradetti V, Pattonieri EF, Carrara C, Bosio F, Piotti G, Soccio G, Esposito P, Albertini R, Dal Canton A, Schaefer I, Himmelseher E, Haller H, Schiffer M, Ryu M, Mulay SR, Miosge N, Gross O, Anders HJ, Zarzecki M, Adamczak M, Wystrychowski A, Gross ML, Ritz E, Wiecek A. Experimental pathology. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Kang MJ, Ryoo B, Ryu M, Koo D, Chang H, Lee J, Kim TW, Kang Y. Venous thromboembolism (VTE) in patients with advanced gastric cancer: An Asian experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Kim JE, Kim HJ, Hong YS, Lee J, Ryu M, Chang H, Jang SJ, Kim M, Yu CS, Kim JC, Kim TW. Microsatellite instability to predict the efficacy of adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Park YS, Ryu M, Park HJ, Kim HJ, Ryoo B, Yook JH, Kim BS, Jang SJ, Kang Y. HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4084] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Ryu M, Park SH, Ryoo B, Im S, Kwon H, Lee SS, Park SR, Kang BW, Kang Y. A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Kang HJ, Ryu M, Kim K, Park YS, Kim WH, Im S, Park SH, Lee KH, Song H, Kang Y. Imatinib efficacy by tumor genotype in Asian patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs): A retrospective study of Korean GIST Study Group (KGSG). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Jo J, Ryu M, Koo D, Ryoo B, Kim HJ, Lee J, Chang H, Kim TW, Choi KD, Lee GH, Jung H, Kim KC, Yook JH, Oh ST, Kim BS, Kim J, Kang Y. Clinical significance of tumor markers as prognostic factors in patients with metastatic gastric cancer receiving first-line chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Ryu M, Choi Y, Kim B, Park Y, Kim H, Jung H, Lee G, Kim K, Yook J, Kang Y. A single-arm, phase II feasibility study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
96 Background: The aim of this study was to evaluate feasibility and safety of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy in patients with potentially resectable adenocarcinoma of stomach or gastroesophageal junction. Methods: Forty-one patients with clinical stage T3-4N0M0 or T2-4N+M0 determined by CT, endoscopic ultrasonography, and laparoscopy were enrolled between DEC 2008 and MAR 2010. Gastrectomy with D2 lymph node dissection was conducted after 3 cycles of DOS chemotherapy. DOS chemotherapy consists of docetaxel 50 mg/m2 iv (day1), oxaliplatin 100 mg/m2 iv (day1), and S-1 40 mg/m2 po bid (days1-14) at 3 weeks interval. After curative gastrectomy, the patients were given 1 year of adjuvant chemotherapy with S-1 (40 mg/m2 D1-28, every 6 weeks). Results: All patients finished the planned neoadjuvant chemotherapy. Twenty-three (56%) patients achieved a partial response, and the remaining 18 patients had stable disease by CT scan after 3 cycles of DOS chemotherapy. No disease progression was observed during the neoadjuvant chemotherapy. A median 4.7 weeks (range, 4.0-7.6) after the start of the 3rd cycle of DOS chemotherapy, 39 (95%) patients underwent R0 resection with no pathologic residual disease in 4 (10%) patients. Hematologic toxicities were common including grade 4 neutropenia (32%), grade 3 thrombocytopenia (17%), and febrile neutropenia (10%). However, hematologic toxicities were generally transient and manageable. There were no grade 3 or 4 non-hematologic toxicities with frequency > 5% of patients. With all toxicities taken together, 21 (51%) patients experienced grade 3 or 4 toxicities (except grade 3 neutropenia). There was no treatment-related death, and surgical complications included only mild wound problem in 4 (10%) patients. Conclusions: In this study, neoadjuvant DOS chemotherapy could induce a sufficient down-staging and R0 resection of locally advanced gastric cancer with mild and manageable toxicities. A phase III randomized trial is planned for evaluating the benefit of neoadjuvant DOS chemotherapy in patients with locally advanced gastric cancer. [Table: see text]
Collapse
Affiliation(s)
- M. Ryu
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - Y. Choi
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - B. Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - Y. Park
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - H. Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - H. Jung
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - G. Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - K. Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - J. Yook
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| | - Y. Kang
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Diagnostic Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Gastroenterology, Asan Medical Center, University of Ulsan
| |
Collapse
|
24
|
Yoon D, Ryu M, Park Y, Lee H, Lee C, Lee J, Ryoo B, Chang H, Kim T, Kang Y. Phase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.93] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
93 Background: To evaluate feasibility with activity and toxicities of everolimus, a novel inhibitor of mammalian target of rapamycin (mTOR), in patients with advanced gastric cancer (AGC) who failed chemotherapy including both fluoropyrimidine and platinum (FP). Methods: Fifty-four patients were enrolled between Jul 2008 and Feb 2010. Everolimus, 10 mg daily, was given until disease progression or unacceptable toxicity. Primary objective was to determine 4-month progression-free survival (PFS) and secondary objectives were to investigate response rate, toxicity and overall survival OS rate. Pre- (n = 28) and on-treatment (n = 19) tumor biopsies were evaluated for phosphorylated (p) mTOR, pS6 kinase1, pS6 and eukaryotic initiation factor 4E binding protein 1 expression. Results: A total of 180 cycles of everolimus were administered with a median of 2 (range, 1-20) cycles in each patient. Two patients (3.7%) achieved confirmed partial response and 19 patients (35.2%) showed stable disease, resulting in a disease control rate of 38.9%. At a median follow-up duration of 8.7 months in surviving patients (range, 3.0–19.4 months), a 4-month PFS rate was 18.4% with a median PFS of 1.7 months (95% CI, 1.5-2.2 months) and a median OS time was 8.3 months (95% CI, 4.5-12.1 months). Peritoneal metastasis (Hazard ratio [HR], 3.97; 95% CI, 1.54-10.23; p = 0.010) and low expression level of pS6Ser240/4 at baseline (HR, 7.64; 95% CI, 2.591-22.51; p = 0.001) were significantly associated with shorter PFS time. Treatment was in general well tolerated. Toxicities of grade 3/4 included anemia (9.4%), thrombocytopenia (9.4%), hepatic dysfunction (11.3%) and pulmonary toxicities (one interstitial pneumonitis and a diffuse alveolar hemorrhage [DAH] case). The DAH and cardiopulmonary dysfunction in another case resulted in treatment-related mortalities. Conclusions: Everolimus monotherapy showed modest activity against AGC refractory to FP. pS6Ser240/4 might be a potential biomarker for the clinical activity of everolimus. The toxicity profile was generally mild. However, careful monitoring for treatment-related pulmonary complication seems to be required. [Table: see text]
Collapse
Affiliation(s)
- D. Yoon
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - M. Ryu
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Y. Park
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - H. Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - C. Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - J. Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - B. Ryoo
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - H. Chang
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - T. Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Y. Kang
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| |
Collapse
|
25
|
Kang Y, Yoo C, Ryoo B, Chang H, Lee J, Beck M, Kim T, Ryu M. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
306 Background: Pharmacokinetic study in patients with gastrointestinal stromal tumors (GISTs) suggested that plasma concentrations of imatinib decrease following long-term exposure. We therefore measured changes in imatinib plasma trough levels (Cmin) after long-term exposure. Methods: Between November 2009 and May 2010, follow-up (FU) imatinib Cmin was measured in 65 patients who received the same dose of imatinib for at least 9 months after a previous baseline (BL) measurement. Total 244 blood samples were obtained (127 at BL and 117 at FU) and plasma level was measured by liquid chromatography-tandem mass spectrometry. Results: Median patient age was 54 years (range, 28–76 years) and 42 (64.6%) patients were male. Sixty-one (93.8%) patients were treated with 400 mg/day imatinib and 4 (6.2%) with 300 mg/day. The median interval from initiation of imatinib to BL test was 6.4 months (range, 0.5–66.6 months), and the median interval between BL and FU test was 13.1 months (range, 9.6–18.4 months). The mean ± standard deviation imatinib Cmin was significantly higher at FU than at BL (1442 ± 693 ng/mL vs 1221 ± 624 ng/mL, p<0.001). The mean inter- and intra-subject variabilities were 49.2% and 25.5%, respectively, at BL, and 44.2% and 20.4%, respectively, at FU. Multivariate analysis showed a significant correlation between the ratio of FU to BL imatinib Cmin and that of albumin (r=-0.397, p=0.001). In per-sample analysis, imatinib Cmin was significantly correlated with age, hemoglobin, albumin, creatinine clearance, previous major gastrectomy and time between initiation of imatinib and plasma level tests. Conclusions: Steady-state imatinib Cmin did not decrease but remained stable in most GIST patients during long-term treatment. Changes in imatinib Cmin were associated with changes in albumin concentration. Monitoring of imatinib Cmin only for concerns about time-dependent decreases in imatinib exposure is not necessary. [Table: see text]
Collapse
Affiliation(s)
- Y. Kang
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - C. Yoo
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - B. Ryoo
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - H. Chang
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - J. Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - M. Beck
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - T. Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - M. Ryu
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| |
Collapse
|
26
|
Son S, Kang Y, Ryu M, Choi B, Jang H, Choi I, Shin H. The Effect of Metallic Implants for the Radiation Therapy in the Spinal Tumor Patients with Metallic Spinal Implants. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Kim K, Ryu M, Yoo C, Ryoo B, Choi D, Chang H, Lee J, Kim T, Beck M, Kang Y. Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Kim J, Hong Y, Lee J, Ryu M, Chang H, Jang S, Kim M, Yu C, Kim T. Association between deficient mismatch repair system and efficacy to irinotecan containing first-line chemotherapy in patients with sporadic metastatic colorectal cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3579] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Ryoo B, Yoon D, Ryu M, Lee S, Hwang S, Suh D, Lee J, Kim T, Chang H, Kang Y. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Ryu M, Yoon D, Ryoo B, Beck M, Choi D, Cho Y, Lee J, Chang H, Kim T, Kang Y. Sunitinib as the second-line therapy for advanced GISTs after failure of imatinib in Korean patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Park Y, Jang S, Lee S, Park H, Ryu M, Ryoo B, Yook J, Kim B, Kim K, Kang Y. Prognostic significance of cell cycle regulating protein expressions in gastric carcinoma patients receiving adjuvant chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Hocke A, Eulitz I, leClaire A, Szymanski K, Ryu M, Becher A, Zahlten J, Dalhoff K, Drömann D, Schneider P, Suttorp N, Hippenstiel S. Streptococcus pneumoniae induzierte Dysfunktion des Glukokortikoid Rezeptor Signalweges in humanen Lungen. Pneumologie 2010. [DOI: 10.1055/s-0030-1251246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Kwon J, Kang M, Kim B, Choi W, Ryu M, Kim M, Yu J, Hong S. Polymorphisms of the GSDMA and GSDMB are Associated with Asthma Susceptibility, Atopy and Bronchial Hyperresponsiveness. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2009.12.897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Ryu M, Ueda T, Saito T, Yasui M, Ishihara K, Sakurai K. Oral environmental factors affecting number of microbes in saliva of complete denture wearers. J Oral Rehabil 2009; 37:194-201. [PMID: 20050985 DOI: 10.1111/j.1365-2842.2009.02042.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The purpose of this study was to clarify which oral environmental factors affected number of microbes in saliva in an edentulous environment. We enrolled 68 edentulous subjects in the study. Numbers of total anaerobic bacteria and Candida species in saliva were determined. Age, sex, un-stimulated salivary flow rate, pH and viscosity of saliva, histatin level in saliva, tongue coating status, tongue pressure, denture plaque status, material of denture base, duration of edentulism, frequency of self oral health care and number of cigarettes per day were also investigated as oral environmental factors. Correlation between number of total anaerobic bacteria or Candida species and each oral environmental factor was determined with the Spearman rank correlation coefficient. Stepwise logistic regression analysis was used to identify which factors were significantly associated with level of total anaerobic bacteria and Candida species. Correlation and stepwise logistic regression analyses revealed associations between un-stimulated salivary flow rate, tongue coating status, denture plaque status or frequency of self oral health care and number of total anaerobic bacteria. The correlation analysis showed a significant correlation between age and number of total anaerobic bacteria. Stepwise logistic analysis revealed associations between pH of saliva or viscosity of saliva and level of anaerobic bacteria; it also revealed associations between histatin level in saliva or un-stimulated salivary flow rate and level of Candida species. We conclude that salivary flow rate, in particular, affects number of salivary microbes in an edentulous environment.
Collapse
Affiliation(s)
- M Ryu
- Oral Health Science Center, Tokyo Dental College, Chiba, Japan.
| | | | | | | | | | | |
Collapse
|
35
|
Jang ER, Ryu M, Park JE, Kim JH, Lee JS, Song K. A new isoquinolinium derivative, Cadein1, preferentially induces apoptosis in p53-defective cancer cells with functional mismatch repair via a p38-dependent pathway. J Biol Chem 2009; 285:2986-95. [PMID: 19948725 DOI: 10.1074/jbc.m109.070466] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We screened a protoberberine backbone derivative library for compounds with anti-proliferative effects on p53-defective cancer cells. A compound identified from this small molecule library, cadein1 (cancer-selective death inducer 1), an isoquinolinium derivative, effectively leads to a G(2)/M delay and caspase-dependent apoptosis in various carcinoma cells with non- functional p53. The ability of cadein1 to induce apoptosis in p53-defective colon cancer cells was tightly linked to the presence of a functional DNA mismatch repair (MMR) system, which is an important determinant in chemosensitivity. Cadein1 was very effective in MMR(+)/p53(-) cells, whereas it was not effective in p53(+) cells regardless of the MMR status. Consistently, when the function of MMR was blocked with short hairpin RNA in SW620 (MMR(+)/p53(-)) cells, cadein1 was no longer effective in inducing apoptosis. Besides, the inhibition of p53 increased the pro-apoptotic effect of cadein1 in HEK293 (MMR(+)/p53(+)) cells, whereas it did not affect the response to cadein1 in RKO (MMR(-)/p53(+)) cells. The apoptotic effects of cadein1 depended on the activation of p38 but not on the activation of Chk2 or other stress-activated kinases in p53-defective cells. Taken together, our results show that cadein1 may have a potential to be an anti-cancer chemotherapeutic agent that is preferentially effective on p53-mutant colon cancer cells with functional MMR.
Collapse
Affiliation(s)
- Eun Ryoung Jang
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Korea
| | | | | | | | | | | |
Collapse
|
36
|
Zang D, Kang Y, Ryu B, Ryu M, Lee S, Kim H, Kim J, Jung J, Kwon J, Kim H. 6546 Phase II study of docetaxel, oxaliplatin and S-1 (DOS) for patients with advanced gastric cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71268-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
37
|
Kang M, Ryoo B, Ryu M, Kang B, Sym S, Lee S, Chang H, Lee J, Kim T, Kang Y. 6535 A phase II study of biweekly chemotherapy with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with advanced gastric cancer after failure of prior chemotherapy including taxane, fluoropyrimidine, and platinum. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71257-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
38
|
Kim C, Lee J, Choi Y, Kang B, Ryu M, Chang H, Kim T, Kang Y. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4559] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4559 Background: We conducted a phase I dose-finding study of sorafenib (S) in combination with capecitabine (X) and cisplatin (P) in patients with previously untreated metastatic or inoperable advanced gastric cancer. Methods: Four dose levels of S, X, and P combination were tested. The doses of S (p.o. daily), X (p.o. on days 1–14), and P (i.v. on day 1) were escalated at the following schedule; level 1: S 400 mg/d, X 1,600 mg/m2/d, P 80 mg/m2; level 2: S 800 mg/d, X 1,600 mg/m2/d, P 80 mg/m2; level 3: S 800 mg/d, X 2,000 mg/m2/d, P 80 mg/m2; level 1A: S 800 mg/d, X 1,600 mg/m2/d, P 60 mg/m2. The cycle was repeated every 3 weeks. Dose limiting toxicities (DLTs) were evaluated only in the first cycles and a standard 3+3 dose escalation design was implemented. Results: A total 21 pts were enrolled in the study. No DLTs were observed at dose level 1 (n=3). One DLT (grade 3 diarrhea) was noted at dose level 2 (n=6), and 2 DLTs (two grade 4 neutropenias longer than 5 days in duration) were observed at dose level 3 (n=6), which made the level 3 dose the maximum tolerated dose (MTD). However, at cycle 2 and thereafter at dose level 2, the relative dose intensity (RDI) of S and X could not be maintained (mostly below 80%) due to the frequent dose reductions and cycle delays. So, we explored a new dose level (1A) between dose level 1 and 2. Since no DLTs were found in 6 patients at level 1A with RDI mostly above 80% throughout the treatment period, level 1A was determined as recommended dose (RD). Most frequent grade 3 and 4 hematologic toxicities were neutropenia (25.0% of cycles), and most frequent grade 2 and 3 non-hematologic toxicities were hand-foot syndrome (9.4%), asthenia (7.0%), and anorexia (5.5%). The objective responses were confirmed in 10 out of 16 patients with measurable lesions (62.5%; 95% CI, 38.8–86.2%). With a median follow-up of 8.1 months, estimated median progression-free survival was 10.0 months (95% CI, 1.6–18.4 months) and median overall survival has not been reached. Conclusions: Diarrhea and neutropenia were DLTs in this S, X, and P combination. The dose schedule of sorafenib 400 mg po bid daily with capecitabine 800 mg/m2 po bid on days 1–14, and cisplatin 60 mg/m2 iv on day 1 in every 3 weeks is recommended for further development in AGC. [Table: see text]
Collapse
Affiliation(s)
- C. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - J. Lee
- Asan Medical Center, Seoul, Republic of Korea
| | - Y. Choi
- Asan Medical Center, Seoul, Republic of Korea
| | - B. Kang
- Asan Medical Center, Seoul, Republic of Korea
| | - M. Ryu
- Asan Medical Center, Seoul, Republic of Korea
| | - H. Chang
- Asan Medical Center, Seoul, Republic of Korea
| | - T. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - Y. Kang
- Asan Medical Center, Seoul, Republic of Korea
| |
Collapse
|
39
|
Kim T, Sym S, Lee S, Ryu M, Lee J, Chang H, Kim H, Shin J, Kang Y, Lee J. A UGT1A1 genotype-directed phase I study of irinotecan (CPT-11) combined with fixed dose of capecitabine in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2554] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2554 Background: The risk of severe toxicity of CPT-11 can be in part explained by polymorphism of UGT1A1. The most common polymorphism in Whites is UGT1A1*28. UGT1A1*6 is another common polymorphism in Asians. We designed a phase I study to investigate UGT1A1 genotype-directed maximum tolerated dose (MTD) of CPT-11 plus fixed dose of capecitabine in patients (pts) with Korean mCRC. Methods: Pts with mCRC screened UGT1A1 genotyping (*28 and *6) and were stratified into one of 3 groups according to the number of defective allele (DA): 0 (none of *28 or *6 allele), 1(only one of *28 or *6 allele), and 2 (*28/*28, *6/*6, or double heterozygous for *28 and *6). The dose of CPT-11 was escalated as following: Level -I:200, I:240, II:280, III:320, IV: 350, V: 380 mg/m2 (IV, once every 3 weeks). Capecitabine (1,000 mg/m2 PO BID) was administered on days 2–15 every 3 weeks. Dose limiting toxicity (DLT) and pharmacokinetic analyses was determined at cycle 1. Results: Forty-two pts, median age 50 years, EOOG performance ≤1 were recruited: 0 DA group (18 pts), 1 DA (18), and 2 DA (6). In 0 DA group, two of six pts experienced DLT at 380 mg/m2 with grade III asthenia (1 pts) and febrile neutropenia (1). In 1 DA group, all of two pts experienced DLT at 380 mg/m2 with grade III asthenia. In 2 DA group, two of three pts experienced DLT at 240 mg/m2 with febrile neutropenia (1) and grade IV neutropenia (1). The MTD was defined as CPT-11 350 mg/m2 for pts with 0 and 1 DA group and CPT-11 200 mg/m2 for pts with 2 DA group, with capecitabine. Median SN-38G/SN-38 AUC was 10.45, 8.78, and 1.66 in pts with 0, 1, and 2 DA group, respectively. Conclusions: CPT-11 dosing by UGT1A1*28 and *6 genotypes is feasible in Korean pts with mCRC. A dose of CPT-11 350 mg/m2 IV for pts with 0 and 1 DA group and CPT-11 200 mg/m2 for pts with 2 DA group, with capecitabine every 3 weeks, is recommended for further study. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Kim
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - S. Sym
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - S. Lee
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - M. Ryu
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - J. Lee
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - H. Chang
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - H. Kim
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - J. Shin
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - Y. Kang
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| | - J. Lee
- Asan Medical Center, Seoul, Republic of Korea; Busan Paik Hospital, Busan, Republic of Korea
| |
Collapse
|
40
|
Kang B, Lee J, Ryu M, Im S, Park S, Kang W, Kim T, Oh D, Jung K, Kang Y. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e21515] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21515 Background: In our previous study, the presence of c-kit mutation as well as tumor size and mitotic count was an independent poor risk factor for relapse after curative resection of primary localized GIST. The patients with all the 3 poor risk factors had only 30% of 2 year relapse free survival rate (RFSR). (Kim, et al. Clin Cancer Res, 2004) It is also well known that c-kit exon 11 mutant GISTs respond better to imatinib treatment than the other mutant or wild type GISTs. Therefore, the patients who have primary localized GISTs with large size, high mitotic count, and c-kit exon 11 mutation may be the best candidate of adjuvant imatinib treatment. In this phase II study, we have evaluated the efficacy and safety of adjuvant imatinib for this patient group. Methods: Patients who underwent complete resection of a primary GIST with 1) c-kit exon 11 mutation, and 2) ≥10 mitoses/50 HPF, or tumor size ≥10 cm, or ≥5 mitoses/50 HPF and tumor size ≥5 cm were eligible. Patients received imatinib 400mg p.o. daily until recurrence of disease, intolerable toxicities, or for 2 years. The primary end point was relapse-free survival (RFS). Results: A total of 47 patients from 4 centers in Korea were enrolled. The median age was 57.0 years. Stomach was the most common primary site (n=31). Median primary tumor size was 7.5cm and median mitoses index was 12/50 HPF. With a median follow-up of 26.9 months, the median RFS and overall survival (OS) have not yet been reached. RFSR was 97.7% at 1-year and 92.7% at 2-years. Six relapses (12.8%) were documented among the 47 patients. The treatments were generally well tolerated. Grade 3–4 toxicities included neutropenia 27.7%, rash 8.5%, constipation 4.3%, anorexia 2.1%, vomiting 2.1%, and pruritis 2.1%. There were no episode of febrile neutropenia and treatment-related death. Conclusions: Postoperative adjuvant imatinib for 2 years were safe and could prolong the RFS in patients with high-risk of recurrence following complete surgical resection of the primary GIST. However, it remains unknown if this benefit in RFS can be translated into OS benefit. So, further follow-up is needed with comparison of OS with historical controls who could be use imatinib after recurrence. [Table: see text]
Collapse
Affiliation(s)
- B. Kang
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - J. Lee
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - M. Ryu
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - S. Im
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - S. Park
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - W. Kang
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - T. Kim
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - D. Oh
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - K. Jung
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| | - Y. Kang
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Sungkyunkwan University School of Medicine, seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
41
|
Lee J, Kim T, Chang H, Ryu M, Sym S, Lee S, Jang G, Lee H, Shin J, Lee J, Kang Y. A phase II and UGT1A1 genotype study of 3-weekly irinotecan with intra-patient dose escalation scheme in patients with advanced gastric cancer failing fluoropyrimidine, platinum, and taxane chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Park I, Lee J, Ryu M, Chang H, Kim T, Sym S, Lee S, Jang G, Bae K, Kang Y. Phase I/II and pharmacokinetic study of combination chemotherapy with S-1 and oxaliplatin in patients with previously untreated metastatic or recurrent gastric cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Kim Y, Kim J, Choi E, Ahn S, Lee S, Kim J, Yu C, Kim T, Chang H, Lee J, Ryu M. The lymph node ratio as prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision and postoperative chemoradiotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Ryu M, Kim EH, Chun M, Kang S, Shim B, Yu YB, Jeong G, Lee JS. Astragali Radix elicits anti-inflammation via activation of MKP-1, concomitant with attenuation of p38 and Erk. J Ethnopharmacol 2008; 115:184-193. [PMID: 17996413 DOI: 10.1016/j.jep.2007.09.027] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2007] [Revised: 09/21/2007] [Accepted: 09/21/2007] [Indexed: 05/25/2023]
Abstract
Although Astragali Radix (Astragalus, AR), the root of Astragalus membranaceus (Fisch) Bunge, is widely used in oriental medicine for tonifying the immune response and improving circulation, the underlying mechanism(s) by which these effects are induced remains unclear. Here, we report that AR displays anti-inflammatory effects in zymosan air-pouch mice by reducing the expression of iNOS, COX-2, IL-6, IL-1beta and TNF-alpha and by decreasing the production of nitric oxide (NO). In a similar manner, AR reduces the expression of IL-6, iNOS, and COX-2 in lipopolysaccharide (LPS)-treated Raw 264.7 cells. We further demonstrate that AR attenuates the activity of p38 and Erk1/2 and stimulates mitogen-activated protein kinase phosphatase-1 (MKP-1) in LPS-treated Raw 264.7 cells. Additionally, AR interferes with the translocation of NFkappaB to the nucleus, subsequently resulting in NFkappaB-dependent transcriptional repression. Taken together, these data reveal that AR has an anti-inflammatory effect that is mediated by the MKP-1-dependent inactivation of p38 and Erk1/2 and inhibition of NFkappaB-mediated transcription. These results imply that the AR herb has a potential anti-inflammatory activity.
Collapse
Affiliation(s)
- Minsook Ryu
- Department of Biological Sciences, Ajou University, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Kang K, Choi B, Jang H, Bae S, Ryu M, Kang Y, Jang J, Choi G, Choi I. Cyberknife stereotactic radiosurgery in patients with primary hepatocellular carcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4645 Background: Conventional radiotherapy has historically played a limited role in the primary treatment of hepatocellular carcinoma (HCC). This study evaluated the effect of Cyberknife stereotactic radiosurgery (SRS) with for both for small primary non-resectable HCC, and for advanced HCC with portal vein tumor thrombosis (PVTT). Methods: From March 2004 to March 2005, thirty one patients with HCC were treated Cyberknife SRS was used for 32 lesions in patients with SRS for primary HCC. There was performed in 22 patients (23 lesions) with targeting to the primary HCC was treated (Group A), and in 9 patients with targeting to the PVTT was treated (Group B). The total SRS doses treated were 30–39 Gy (median, 36 Gy) to the 70–85%, 3 fractions and the target volume was of 3.6–57.3 cc (median, 25.2 cc). Results: The median follow up was 10.5 months. A complete response (CR) was achieved in 10 lesions, a partial response (PR) in 13 lesions, stable disease was noted in 6 lesions, and disease progression in 3 lesions. The response rate (CR+PR) was 71.9% (group A: 82.6%, group B: 44.4%). The level of serum alpha-fetoprotein after the treatment was decreased significantly in 17 patients (54.8%) (group A: 54.5%, group B: 55.5%). Complications were observed in 15 patients, among them, greater than grade 3 complication was observed in two patients of group A (gastric ulcer bleeding (1), liver necrosis (1)). Conclusions: These results suggest that Cyberknife SRS could be considered as an effective and safe treatment for primary HCC. For PVTT, Cyberknife SRS as the only curative tool, and produced acceptable local control in this study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Kang
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - B. Choi
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - H. Jang
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - S. Bae
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - M. Ryu
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - Y. Kang
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - J. Jang
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - G. Choi
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| | - I. Choi
- Gyeongsang National University, Jinju, Republic of Korea; The Catholic University of Korea, Seoul, Republic of Korea
| |
Collapse
|
46
|
Lee S, Lee S, Chun Y, Kim M, Chang H, Kim T, Ryu M, Lee J, Lee J, Kang Y. Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9007 Introduction: Although pyridoxine has been used empirically for the prevention of HFS associated with capecitabine, its efficacy has not been proven yet. We performed a prospective randomized double-blind study to determine whether pyridoxine can prevent the development of HFS when given concurrently with capecitabine. Method: Chemotherapy-naive patients (pts) with gastrointestinal tract cancers who were going to have capecitabine-containing chemotherapy were randomized to receive either oral pyridoxine (200 mg/day) or placebo daily during chemotherapy after stratified by chemotherapy regimen: 1) capecitabine alone, 2) capecitabine and cisplatin, or 3) docetaxel, capecitabine, and cisplatin. The patients were observed until grade 2 or 3 HFS (by NCI CTC version 2.0) developed or capecitabine containing chemotherapy ended. When grade 2 or 3 HFS developed in pts in placebo group, the pts were randomized again to receive either pyridoxine or placebo for next cycle of chemotherapy in order to determine whether pyridoxine could improve the HFS. Result: From Jun 2004 to Oct 2005, total 389 pts were entered onto the study. But, 29 pts (15 in placebo group and 14 in pyridoxine group) were excluded from the study because of ineligibility or pts’ refusal. Pts’ characteristics were well balanced between the 2 groups. Grade 2 or 3 HFS developed in 55 of 180 (30.6%) pts in placebo group and in 57 of 180 (31.7%) pts in pyridoxine group. (p=0.788) The median cycles of chemotherapy to grade 2 or 3 HFS was 3 in both groups. The mean cumulative dose of capecitabine until occurrence of grade 2 or 3 HFS was not different statistically between the two groups. (221,157.5 mg/m2 vs. 259,808.5 mg/m2, p=0.788). Total 44 of 55 pts in placebo group who had grade 2 or 3 HFS were randomized to receive either placebo or pyridoxine at next cycle. There was no significant difference between the two groups in the proportion of pts with improvement of HFS (43% vs 48%, p=0.94). Conclusion: These results indicated that pyridoxine is not effective for the prevention of HFS associated with capecitabine therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Lee
- Asan Medical Center, Seoul, Republic of Korea
| | - S. Lee
- Asan Medical Center, Seoul, Republic of Korea
| | - Y. Chun
- Asan Medical Center, Seoul, Republic of Korea
| | - M. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - H. Chang
- Asan Medical Center, Seoul, Republic of Korea
| | - T. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - M. Ryu
- Asan Medical Center, Seoul, Republic of Korea
| | - J. Lee
- Asan Medical Center, Seoul, Republic of Korea
| | - J. Lee
- Asan Medical Center, Seoul, Republic of Korea
| | - Y. Kang
- Asan Medical Center, Seoul, Republic of Korea
| |
Collapse
|
47
|
Lee J, Kang H, Kang Y, Ryu M, Chang H, Kim T, Sohn H, Kim H, Lee J. Phase I/II study of combination chemotherapy with S-1 and cisplatin every 3 week schedule in patients with metastatic or recurrent gastric cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15066 Background: S-1 plus cisplatin has been reported to be highly active in advanced gastric cancer (AGC). The objectives of this study were to define the maximal-tolerated dose (MTD) of S-1, given for 2 weeks separated by 1 week rest, with a fixed dose of cisplatin, and to determine the activity and safety of this combination regimen at the recommended dose (RD) when used as the first line treatment of AGC. Methods: Cisplatin was fixed at a dose of 60 mg/m2 on D1 and the starting dose of S-1 was 30 mg/m2 bid (level I) on D1 to D14 every 3 weeks. The dose of S-1 was increased by 5 mg/m2 bid up to 50 mg/m2 bid (level V) unless MTD was achieved. At every level, a cohort of 3 patients (pts), which could be expanded to 6 pts, was studied. Dose-limiting toxicities (DLTs) were assessed for the first 2 cycles. Results: From February 2004 to January 2006, 62 eligible pts were enrolled. In phase I (N=21), DLTs occurred at level V (S-1 50 mg/m2 bid), with 2 of 3 pts developing G3 diarrhea or febrile neutropenia. The RD was determined at level IV (45 mg/m2 bid) because only 1 DLT occurred out of 6 pts at this level. After the first 20 pts (series I) were enrolled in phase II, the protocol was amended; the S-1 dose was reduced down to 40 mg/m2 bid (level III, series II, N=23) because of poor bone marrow recovery and resultant treatment delay. At the time of analysis, a total of 272 cycles of chemotherapy were administered. The median age was 52 years (28–70) and ECOG PS was 0/1 in 98% of pts. The objective response was observed in 20(47%; 95% CI, 36–66%) of 43 pts. SD was achieved in 15 (35%) pts. With a median FU of 12.1 months (range 9.8–23.3) for all survivors, median PFS was 5.3 months (95% CI, 4.6–6.0 months) with a median OS of 10.0 months (95% CI, 5.1–14.8 months). G3–4 toxicities included neutropenia (33%), anemia (31%), anorexia (24%), and asthenia (14%); however severe febrile neutropenia, abdominal pain, and stomatitis were never observed. Conclusions: The cisplatin plus S-1 regimen incorporating 2-weeks on and 1-week off is highly active against gastric adenocarcinoma with favorable toxicitiy profiles in Korean patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Lee
- Asan Medical Center, Seoul, Republic of Korea
| | - H. Kang
- Asan Medical Center, Seoul, Republic of Korea
| | - Y. Kang
- Asan Medical Center, Seoul, Republic of Korea
| | - M. Ryu
- Asan Medical Center, Seoul, Republic of Korea
| | - H. Chang
- Asan Medical Center, Seoul, Republic of Korea
| | - T. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - H. Sohn
- Asan Medical Center, Seoul, Republic of Korea
| | - H. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - J. Lee
- Asan Medical Center, Seoul, Republic of Korea
| |
Collapse
|
48
|
Sym S, Chang H, Ryu M, Lee J, Kim T, Yook J, Oh S, Kim B, Kang Y. A phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine and cisplatin (DXP) in patients with advanced unresectable or intra-abdominal metastatic gastric cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4640] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4640 Background: The prognosis of gastric cancer is dismal once R0 resection is impossible due to local invasion or distant metastasis. Previous studies have suggested the possible efficacy of neoadjuvant chemotherapy for the patients with locally advanced gastric cancer (AGC). The aim of the present study was to evaluate the feasibility, the impact on R0 resection of neoadjuvant chemotherapy in locally advanced, unresectable or intra-abdominal metastatic gastric cancer Methods: Patients with advanced gastric cancer, clinically unresectable because of local invasion or intra-abdominal metastasis in paraaortic lymph nodes and/or peritoneum based on CT scan were entered into this study. Preoperative chemotherapy consisted of docetaxel 60 mg/m2 IV on day 1, cisplatin 60 mg/m2 IV on day 1, and capecitabine 1,875 mg/m2/day PO on days 1 - 14 every 21 days. After 2 cycles of chemotherapy, the tumors were evaluated. Unless disease progression was encountered, surgery was performed after total 3 - 6 cycles of chemotherapy and followed by two cycle of adjuvant therapy with the same regimen if R0 resection was done. Results: Total 49 patients were accrued. Among them, 36 (74%) could undergo surgery, and 31 (63%) had R0 resection. R0 resection was possible in 15 (71%) of 21 patients with initially unresectable T4 lesions and in 12 (70%) of 17 patients with paraaortic lymph node enlargement, while only in 3 (42%) of 7 patients with suspicious peritoneal seeding. After a median follow up of 18.2 months for the surviving patients, median overall survival and progression free survival of total enrolled patients were 19 months (95% C.I, 10.5 - 27.4) and 11.6 months (95% C.I, 9.6 - 13.7), respectively. Among 31 patients who underwent R0 resection, median OS was 33.4 months and median PFS was 18.2 months. Major toxicity was neutropenia and grade 3/4 neutropenia occurred in 77% of patients, but there was only 4% of neutropenic fever and no treatment related mortality. Postoperative morbidities were observed in 4 patients. Conclusions: These data suggested that neoadjuvant DXP chemotherapy could offer a reasonable chance for curative surgery in AGC patients with local invasion or paraaortic lymph node enlargement. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Sym
- Asan Medical Center, Seoul, Republic of Korea
| | - H. Chang
- Asan Medical Center, Seoul, Republic of Korea
| | - M. Ryu
- Asan Medical Center, Seoul, Republic of Korea
| | - J. Lee
- Asan Medical Center, Seoul, Republic of Korea
| | - T. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - J. Yook
- Asan Medical Center, Seoul, Republic of Korea
| | - S. Oh
- Asan Medical Center, Seoul, Republic of Korea
| | - B. Kim
- Asan Medical Center, Seoul, Republic of Korea
| | - Y. Kang
- Asan Medical Center, Seoul, Republic of Korea
| |
Collapse
|
49
|
Cho A, Asano T, Yamamoto H, Nagata M, Takiguchi N, Kainuma O, Souda H, Gunji H, Miyazaki A, Nojima H, Ikeda A, Matsumoto I, Ryu M, Makino H, Okazumi S. Laparoscopy-assisted hepatic lobectomy using hilar Glissonean pedicle transection. Surg Endosc 2007; 21:1466-8. [PMID: 17356935 DOI: 10.1007/s00464-007-9253-5] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2006] [Accepted: 01/25/2007] [Indexed: 02/06/2023]
Abstract
Although many reports have described laparoscopic minor liver resections, major hepatic resection, including right or left lobectomy, has not been widely developed because of technical difficulties. This article describes a new technique for performing laparoscopy-assisted right or left hepatic lobectomy using hilar Glissonean pedicle transection. Laparoscopic mobilization of the right or left hepatic lobe is performed, including dissection of the round, faliciform, triangular, and coronary ligaments. The right or left Glissonean pedicle is encircled and divided laparoscopically. A parenchymal dissection is then performed though the upper median or right subcostal incision, through which the resected liver is removed. We successfully performed this procedure in 6 patients without blood transfusion or serious complications. Laparoscopy-assisted hepatic lobectomy using hilar Glissonean pedicle transection can be feasible and safe in highly selected patients.
Collapse
Affiliation(s)
- A Cho
- Department of Gastroenterological Surgery, Chiba Cancer Center Hospital, 666-2 Nitonachou, Chuouku, Chiba, 260-8717, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Park Y, Lee J, Ryoo B, Ryu M, Yang S, Kim B, Shin D, Chang H, Kim T, Kang Y. A phase II study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4079 Background: The combination chemotherapy of capecitabine and cisplatin showed considerable activity and good feasibility in patients with advanced gastric cancer. Oxaliplatin has a more favorable toxicity profile compared to cisplatin. The purpose of the study is to evaluate the efficacy and toxicity of capecitabine plus oxaliplatin combination chemotherapy in previously untreated patients with advanced gastric carcinoma. Methods: Patients received intravenous oxaliplatin 130 mg/m2 over 2 hours on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1–14, every 3 weeks. Treatment was continued until progression of disease or intolerable toxicities with a maximum of 8 cycles. All the measurability and response evaluations were reviewed and confirmed by one investigator. Results: Total 54 patients were enrolled (37 men, 17 women). The median age was 57 years (range 29–70). Among these 54 patients, fifty-two patients were evaluable. A total 311 cycles of chemotherapy were delivered. The overall response rate was 63% (95% CI, 50–76%), with complete response in 2 patient and partial responses in 32 patients. After a median follow-up of 13 months, median progression-free survival was 5.8 months (95% CI, 4.4–7.2 months); median overall survival was 11.9 months (95% CI, 8.8–15.1 months). The treatment was generally well tolerated. The most common haematological adverse event was anaemia (70% of patients). Grade 3- 4 neutropenia was observed in 4 patients and neutropenic fever was experienced in only 1 patient. Four patients had G3 thrombocytopenia, which was accompanied by G3 gastrointestinal bleeding. The most common non-haematological toxicities were neuropathy (70%), vomiting (50%), diarrohea (33%), and hand-foot syndrome (39%). But, G3–4 toxicities were rare. There was one treatment related death which was associated with grade IV neutropenic sepsis. Conclusion: XELOX was active and well tolerated as a first-line therapy for advanced gastric carcinoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Park
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - J. Lee
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - B. Ryoo
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - M. Ryu
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - S. Yang
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - B. Kim
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - D. Shin
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - H. Chang
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - T. Kim
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| | - Y. Kang
- Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Seoul Veterans Hospital, Seoul, Republic of Korea; Gil Medical Center, Incheon, Republic of Korea
| |
Collapse
|